Published in Neth Heart J on June 01, 2013
Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun (2015) 0.99
Arrhythmogenic cardiomyopathy: diagnosis, genetic background, and risk management. Neth Heart J (2014) 0.91
Altered myocardial calcium cycling and energetics in heart failure-a rational approach for disease treatment. Cell Metab (2015) 0.89
Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. Sci Rep (2016) 0.76
Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol (2016) 0.76
Clinical characterisation and risk stratification of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy ≥50 years of age. Neth Heart J (2016) 0.75
Cardiovascular genetics: technological advancements and applicability for dilated cardiomyopathy. Neth Heart J (2015) 0.75
The phospholamban p.Arg14del founder mutation in Dutch patients with arrhythmogenic cardiomyopathy. Neth Heart J (2013) 0.75
Nature and Nurture in Arrhythmogenic Right Ventricular Cardiomyopathy - A Clinical Perspective. Arrhythm Electrophysiol Rev (2015) 0.75
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34
Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation (2003) 5.85
Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol (2003) 5.05
Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell (1994) 4.47
Arrhythmogenic right ventricular cardiomyopathy. Lancet (2009) 4.46
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science (2003) 3.71
Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest (2003) 2.56
Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation (2007) 2.56
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med (2001) 2.35
Inherited cardiomyopathies. N Engl J Med (2011) 2.25
Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet (2009) 2.19
A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci U S A (2006) 2.05
Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet (2010) 1.98
Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu Rev Med (2010) 1.86
Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol (2007) 1.86
Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol (2007) 1.80
The genetics of dilated cardiomyopathy. Curr Opin Cardiol (2010) 1.76
Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc (2005) 1.65
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail (2012) 1.51
Founder mutations among the Dutch. Eur J Hum Genet (2004) 1.21
Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol (2007) 1.13
Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy. Circ Cardiovasc Genet (2010) 1.10
N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J (2009) 1.08
Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Heart Rhythm (2009) 1.07
Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol (2006) 1.04
Molecular genetics of arrhythmogenic right ventricular cardiomyopathy: emerging horizon? Curr Opin Cardiol (2007) 1.01
Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p.S13F and p.N342D. Neth Heart J (2012) 0.99
Mutations in the human phospholamban gene in patients with heart failure. Am Heart J (2011) 0.99
Founder mutations in the Netherlands: SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterised families worldwide. Neth Heart J (2009) 0.96
PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing. Am Heart J (2011) 0.96
Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J (2010) 0.92
Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy. Neth Heart J (2011) 0.91
Recurrent and founder mutations in the Netherlands : Plakophilin-2 p.Arg79X mutation causing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Neth Heart J (2010) 0.91
Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J (2002) 3.01
A sodium-channel mutation causes isolated cardiac conduction disease. Nature (2001) 2.67
Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation (2010) 2.53
QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet (1999) 2.48
Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy. Neurology (2008) 2.21
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol (2001) 1.92
Is T-wave alternans testing feasible in candidates for prophylactic implantable defibrillators? Neth Heart J (2011) 1.89
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. Eur Heart J (2001) 1.87
Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology (2001) 1.84
Bibliometric data in clinical cardiology revisited. The case of 37 Dutch professors. Neth Heart J (2011) 1.79
Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet (2005) 1.78
Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J (2000) 1.75
Novel Brugada syndrome-causing mutation in ion-conducting pore of cardiac Na+ channel does not affect ion selectivity properties. Acta Physiol Scand (2005) 1.67
The fibrosis marker galectin-3 and outcome in the general population. J Intern Med (2011) 1.62
Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery: a prospective study. Europace (2003) 1.61
[Initial diagnostic strategy in the case of transient losses of consciousness: the importance of the medical history]. Ned Tijdschr Geneeskd (2003) 1.55
Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol (1999) 1.54
Genetic knowledge and counselling skills of Dutch cardiologists: sufficient for the genomics era? Eur Heart J (2003) 1.52
Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. Eur Heart J (2002) 1.48
Retrospective detection of exposure to organophosphorus anti-cholinesterases: mass spectrometric analysis of phosphylated human butyrylcholinesterase. Chem Res Toxicol (2002) 1.47
[Genetic identification of patients and families with a long-QT syndrome: large regional differences in the result of 10 years]. Ned Tijdschr Geneeskd (2007) 1.46
Paroxysmal atrial fibrillation, quality of life and neuroticism. Neth J Med (2005) 1.45
MicroSAGE: a modified procedure for serial analysis of gene expression in limited amounts of tissue. Nucleic Acids Res (1999) 1.42
[Implantable cardioverter-defibrillator in the treatment of two patients with an increased risk of sudden cardiac death]. Ned Tijdschr Geneeskd (2004) 1.40
Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. J Am Coll Cardiol (2000) 1.40
The works of Dirk Durrer (1918-1984). Neth Heart J (2012) 1.39
[Medication for ADHD and the risk of cardiovascular mortality]. Ned Tijdschr Geneeskd (2006) 1.39
Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet (2011) 1.38
Electrophysiological changes of angiotensin-converting enzyme inhibition after myocardial infarction. J Card Fail (2000) 1.37
[Treatment of hirsutism]. Ned Tijdschr Geneeskd (1994) 1.37
Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res (1999) 1.34
The Hirsch-index: a simple, new tool for the assessment of scientific output of individual scientists: The case of Dutch professors in clinical cardiology. Neth Heart J (2009) 1.30
Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J (1994) 1.29
N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. Neth Heart J (2008) 1.26
The many faces of aggressive aortic pathology: Loeys-Dietz syndrome. Neth Heart J (2008) 1.24
Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol (1988) 1.21
Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasc Res (1999) 1.17
Telomere length is shorter in healthy offspring of subjects with coronary artery disease: support for the telomere hypothesis. Heart (2008) 1.16
Perceived and observed mother-child interaction at time of hospitalization and release in postpartum depression and psychosis. Arch Womens Ment Health (2008) 1.14
Maternal psychological distress and fetal growth trajectories: the Generation R Study. Psychol Med (2009) 1.14
The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome. J Med Genet (2003) 1.13
Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. Circulation (1995) 1.13
The cardiac sodium channel displays differential distribution in the conduction system and transmural heterogeneity in the murine ventricular myocardium. Basic Res Cardiol (2009) 1.11
Desmin-related myopathy. Clin Genet (2010) 1.05
Telomere length loss due to smoking and metabolic traits. J Intern Med (2013) 1.04
Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis. Neurology (2009) 1.00
Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer (2004) 0.99
Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p.S13F and p.N342D. Neth Heart J (2012) 0.99
Family and population strategies for screening and counselling of inherited cardiac arrhythmias. Ann Med (2004) 0.98
Founder mutations in the Netherlands: SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterised families worldwide. Neth Heart J (2009) 0.96
Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol (1997) 0.96
Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J (1988) 0.95
Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome. Neth Heart J (2010) 0.94
First experience with the wearable cardioverter defibrillator in the Netherlands. Neth Heart J (2012) 0.94
Left cardiac sympathetic denervation in the Netherlands for the treatment of inherited arrhythmia syndromes. Neth Heart J (2014) 0.93
Novel KCNQ1 and HERG missense mutations in Dutch long-QT families. Hum Mutat (1999) 0.92
Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J (2010) 0.92
Association between anxiety but not depressive disorders and leukocyte telomere length after 2 years of follow-up in a population-based sample. Psychol Med (2012) 0.92
Carrier detection of Batten disease (juvenile neuronal ceroid-lipofuscinosis). Am J Med Genet (1995) 0.91
Arrhythmogenic cardiomyopathy: diagnosis, genetic background, and risk management. Neth Heart J (2014) 0.91
Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy. Neth Heart J (2011) 0.91
The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease. Neth Heart J (2011) 0.91
Recurrent and founder mutations in the Netherlands : Plakophilin-2 p.Arg79X mutation causing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Neth Heart J (2010) 0.91
Role of the autonomic nervous system in vagal atrial fibrillation. Heart (2003) 0.90
Rationale and design of the CAREFUL study : The yield of CARdiogenetic scrEening in First degree relatives of sudden cardiac and UnexpLained death victims <45 years. Neth Heart J (2010) 0.90
Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. Neurology (2011) 0.90
Neonatal lactic acidosis, complex I/IV deficiency, and fetal cerebral disruption. Neuropediatrics (2005) 0.90
Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur J Clin Invest (2005) 0.89
Cardiac assessment of patients with late stage Duchenne muscular dystrophy. Neth Heart J (2009) 0.88
Can parents adjust to the idea that their child is at risk for a sudden death?: Psychological impact of risk for long QT syndrome. Am J Med Genet A (2005) 0.88
Predictors of outcome after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Special interest for the septal coronary anatomy. Neth Heart J (2013) 0.87
High distress in parents whose children undergo predictive testing for long QT syndrome. Community Genet (2005) 0.87
Reversion of tachycardiomyopathy after beta-blocker. Lancet (1993) 0.87
Prognostic value of microvolt T-wave alternans in a real-world ICD population. Twente ICD Cohort Studie (TICS). Neth Heart J (2014) 0.87
Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol (2011) 0.86
Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer (2009) 0.86
The fragile X syndrome: no evidence for any recent mutations. J Med Genet (1993) 0.86
Atrial fibrillation and sinus node dysfunction. J Am Coll Cardiol (2001) 0.86
Bohring syndrome. Am J Med Genet (2000) 0.86
Preferences of cardiologists and clinical geneticists for the future organization of genetic care in hypertrophic cardiomyopathy: a survey. Clin Genet (2005) 0.85
[Cardiac rehabilitation in patients with a congenital heart disease, an implantable cardioverter defibrillator or chronic heart failure]. Ned Tijdschr Geneeskd (2004) 0.85
Clinical implementation of guidelines for cardioverter defibrillator implantation: lost in translation? Neth Heart J (2007) 0.84
Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Neth Heart J (2009) 0.84